Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.6.4 (
chondroitinase
)
2,039
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Calpain I is a calcium-dependent cysteine proteinase that has been recently shown to degrade proteoglycan in vitro. The authors injected
calpain
I, which was purified from human red blood cells, into the intervertebral discs of rabbits. Roentgenograms showed disc space narrowing 1 week after the injection. Histologically, proteoglycan of the nucleus pulposus and anulus fibrosus decreased and notochordal cells in the nucleus pulposus almost disappeared. Biochemical data of the nucleus pulposus showed that the amounts of smaller proteoglycans increased 1 and 4 weeks after the injection. Eight weeks after the injection, histologic and biochemical data showed recovery compared with the data 1 week after injection. These findings show that
calpain
I is as potent an enzyme as
chondroitinase
ABC and has milder chemonucleolytic action than chymopapain. Regarding its possible clinical application, autogenous
calpain
I as purified from the patient's own red blood cells may have advantages over chymopapain and
chondroitinase
ABC in that it will prevent anaphylactic reaction.
...
PMID:Chemonucleolysis with calpain I in rabbits. 843 17
Transforming growth factor-beta (TGF-beta) is normally secreted in a latent form, and plasmin-mediated proteolytic cleavage of latency-associated peptide (LAP), a component of latent TGF-beta complex that makes the complex inactive, activates latent TGF-beta. In the present study, we investigated the possible involvement of
calpain
, one of the cysteine proteases, in the activation of latent TGF-beta. When recombinant latent TGF-beta was incubated with
calpain
(1-10 u/ml) in a test tube,
calpain
cleaved LAP and released mature TGF-beta from the latent complex. When
calpain
was applied to cultured bovine capillary endothelial (BCE) cells, a low concentration of
calpain
(0.05-0.1 u/ml) inhibited the migration and proliferation of the cells, and these inhibitory effects were abrogated by anti-TGF-beta antibody as well as by calpain inhibitor peptide, but not by alpha2-antiplasmin, a specific inhibitor of plasmin. Active TGF-beta was detected in the conditioned medium of BCE cells collected in the presence of
calpain
. Chemical cross-linking of (125)I-
calpain
to BCE cells followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis indicated that
calpain
bound to the cell surface through
chondroitinase
ABC-sensitive proteoglycan. In addition, treatment of the BCE cells with
chondroitinase
ABC abrogated the inhibitory effect of
calpain
on the migration of these cells. Our data thus suggest that
calpain
is able to activate latent TGF-beta through a mechanism independent of plasmin. This activation is efficient in the presence of cells, and
calpain
binds to the cell surface via proteoglycan and activates latent TGF-beta, which is targeted to the same surface.
...
PMID:Cell-associated activation of latent transforming growth factor-beta by calpain. 942 5